Reduced hydroxymethylation characterizes medulloblastoma while TET and IDH genes are differentially expressed within molecular subgroups

[1]  Wei Zhang,et al.  Author Correction: 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers , 2019, Cell Research.

[2]  Hu Li,et al.  Loss of TET1 facilitates DLD1 colon cancer cell migration via H3K27me3‐mediated down‐regulation of E‐cadherin , 2018, Journal of cellular physiology.

[3]  J. Qiao,et al.  TET1 inhibits EMT of ovarian cancer cells through activating Wnt/β-catenin signaling inhibitors DKK1 and SFRP2. , 2017, Gynecologic oncology.

[4]  Yan Zhang,et al.  5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages , 2017, Cell Research.

[5]  Sirintra Nakjang,et al.  Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study , 2017, The Lancet. Oncology.

[6]  Zhaoli Chen,et al.  Decreased 5-hydroxymethylcytosine levels correlate with cancer progression and poor survival: a systematic review and meta-analysis , 2016, Oncotarget.

[7]  K. Kaestner,et al.  Epigenetic regulation of intestinal stem cells by Tet1-mediated DNA hydroxymethylation , 2016, Genes & development.

[8]  P. Hauser,et al.  High expression of DNA methyltransferases in primary human medulloblastoma. , 2016, Folia neuropathologica.

[9]  M. Tomková,et al.  5-hydroxymethylcytosine marks regions with reduced mutation frequency in human DNA , 2016, eLife.

[10]  T. Horii,et al.  5-Hydroxymethylcytosine Marks Sites of DNA Damage and Promotes Genome Stability. , 2016, Cell reports.

[11]  A. Riggs,et al.  Downregulation of TLX induces TET3 expression and inhibits glioblastoma stem cell self-renewal and tumorigenesis , 2016, Nature Communications.

[12]  F. Lescroart,et al.  Uncovering the Number and Clonal Dynamics of Mesp1 Progenitors during Heart Morphogenesis , 2015, Cell reports.

[13]  C. James,et al.  Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation. , 2015, Cell reports.

[14]  J. Cullen,et al.  Treatment of Pancreatic Cancer with Pharmacological Ascorbate. , 2015, Current pharmaceutical biotechnology.

[15]  Sheng F Huang,et al.  Reduction of global 5-hydroxymethylcytosine is a poor prognostic factor in breast cancer patients, especially for an ER/PR-negative subtype , 2015, Breast Cancer Research and Treatment.

[16]  Mitsuyoshi Nakao,et al.  TET family proteins and 5-hydroxymethylcytosine in esophageal squamous cell carcinoma , 2015, Oncotarget.

[17]  Derek J Van Booven,et al.  Epigenetic reprogramming of melanoma cells by vitamin C treatment , 2015, Clinical Epigenetics.

[18]  M. Biel,et al.  TET3 is recruited by REST for context-specific hydroxymethylation and induction of gene expression. , 2015, Cell reports.

[19]  S. Vowler,et al.  5-hydroxymethylcytosine marks promoters in colon that resist DNA hypermethylation in cancer , 2015, Genome Biology.

[20]  D. Gao,et al.  Role of 5-hydroxymethylcytosine level in diagnosis and prognosis prediction of intrahepatic cholangiocarcinoma , 2015, Tumor Biology.

[21]  Xiaohua Li,et al.  TET1-mediated different transcriptional regulation in prostate cancer. , 2015, International journal of clinical and experimental medicine.

[22]  S. Oliviero,et al.  TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway , 2014, Oncogene.

[23]  B. Frycz,et al.  Decreased expression of ten-eleven translocation 1 protein is associated with some clinicopathological features in gastric cancer. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[24]  G. Pan,et al.  Vitamin C modulates TET1 function during somatic cell reprogramming , 2013, Nature Genetics.

[25]  Juan I. Young,et al.  Ascorbate-induced generation of 5-hydroxymethylcytosine is unaffected by varying levels of iron and 2-oxoglutarate. , 2013, Biochemical and biophysical research communications.

[26]  Zechen Chong,et al.  Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. , 2013, Journal of the American Chemical Society.

[27]  Mohammad M. Karimi,et al.  Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells , 2013, Nature.

[28]  Limei Liu,et al.  Decrease of 5-Hydroxymethylcytosine Is Associated with Progression of Hepatocellular Carcinoma through Downregulation of TET1 , 2013, PloS one.

[29]  Juan I. Young,et al.  Ascorbate Induces Ten-Eleven Translocation (Tet) Methylcytosine Dioxygenase-mediated Generation of 5-Hydroxymethylcytosine*♦ , 2013, The Journal of Biological Chemistry.

[30]  Z. Ling,et al.  Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation , 2013, Oncogene.

[31]  Tao Wang,et al.  Genome-wide DNA hydroxymethylation changes are associated with neurodevelopmental genes in the developing human cerebellum. , 2012, Human molecular genetics.

[32]  Scott L. Pomeroy,et al.  Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.

[33]  N. Smoll,et al.  The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children , 2012, Journal of Clinical Neuroscience.

[34]  U. Schüller,et al.  Low values of 5‐hydroxymethylcytosine (5hmC), the “sixth base,” are associated with anaplasia in human brain tumors , 2012, International journal of cancer.

[35]  Abraham J. Khorasani,et al.  Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma , 2012, Cell.

[36]  W. Nelson,et al.  Decreased 5-Hydroxymethylcytosine Is Associated with Neural Progenitor Phenotype in Normal Brain and Shorter Survival in Malignant Glioma , 2012, PloS one.

[37]  Shane S. Sturrock,et al.  Geneious Basic: An integrated and extendable desktop software platform for the organization and analysis of sequence data , 2012, Bioinform..

[38]  H. Aburatani,et al.  Loss of 5‐hydroxymethylcytosine is accompanied with malignant cellular transformation , 2012, Cancer science.

[39]  K. Helin,et al.  DNA methylation: TET proteins—guardians of CpG islands? , 2012, EMBO reports.

[40]  G. Schackert,et al.  5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. , 2011, Cancer research.

[41]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.

[42]  A. Tefferi,et al.  Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients , 2011, Leukemia.

[43]  C. Iacobuzio-Donahue,et al.  Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers , 2011, Oncotarget.

[44]  M. Hatten,et al.  Development and cancer of the cerebellum , 2011, Trends in Neurosciences.

[45]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[46]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[47]  S. Croul,et al.  The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma , 2010, Oncogene.

[48]  C. Knudson,et al.  Mechanisms of Ascorbate-Induced Cytotoxicity in Pancreatic Cancer , 2010, Clinical Cancer Research.

[49]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[50]  Andrey Korshunov,et al.  Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.

[51]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[52]  Eric Bouffet,et al.  Core neurocognitive functions in children treated for posterior fossa tumors. , 2008, Neuropsychology.

[53]  T. MacDonald,et al.  Medulloblastoma in childhood: new biological advances , 2007, The Lancet Neurology.

[54]  B. Scheithauer,et al.  The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.

[55]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[56]  D. Louis,et al.  Adult Medulloblastoma: Prognostic Factors and Patterns of Relapse , 2000, Neurosurgery.

[57]  L. Rorke,et al.  Medulloblastoma: clinical and biologic aspects. , 1999, Neuro-oncology.

[58]  David R. Liu,et al.  Conversion of 5-Methylcytosine to 5- Hydroxymethylcytosine in Mammalian DNA by the MLL Partner TET1 , 2009 .

[59]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[60]  K. Pearson.  Mathematical Contributions to the Theory of Evolution. III. Regression, Heredity, and Panmixia , 1896 .